Therapeutic agent for soft tissue sarcoma

Abstract

A therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma) contains a histone deacetylase inhibitor (particularly compound of formula I) as an active ingredient

1 - 8 . (canceled)  
     
     
         9 . A method for treating soft tissue sarcoma, which comprises administering an effective amount of a histone deacetylase inhibitor.  
     
     
         10 . The method of  claim 9 , wherein the soft tissue sarcoma is synovial sarcoma.  
     
     
         11 . The method of  claim 10 , wherein the synovial sarcoma is SYT-SSX protein expressing sarcoma.  
     
     
         12 . The method of  claim 9 , wherein the soft tissue sarcoma is selected from the group consisting of malignant fibrous histocytoma, liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, fibrosarcoma, malignant schwannoma, angiosarcoma, and clear cell sarcoma.  
     
     
         13 - 16 . (canceled)  
     
     
         17 . The method of  claim 9 , wherein the histone deacetylase inhibitor is SAHA or trichostatin A.  
     
     
         18 . The method of  claim 17 , wherein the soft tissue sarcoma is synovial sarcoma.  
     
     
         19 . The method of  claim 18 , wherein the synovial sarcoma is SYT-SSX protein expressing sarcoma.  
     
     
         20 . The method of  claim 17 , wherein the soft tissue sarcoma is selected from the group consisting of malignant fibrous histocytoma, liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, fibrosarcoma, malignant schwannoma, angiosarcoma, and clear cell sarcoma.  
     
     
         21 - 23 . (canceled)